PHARMAC announces exciting new opportunities for improved health. Consultations close 25 May.
Medicines and medical devices funded for use in the community (Section B) and in DHB hospitals (Section H).
Citalopram, cholecalciferol, haemophilia treatments, mirtazapine, respiratory devices, sumatriptan, ziprasidone, zopiclone.
Consultations, notifications, tenders, RFPs, media.
How medicines are funded, about medicines, making best use of medicines, hospital pharmaceuticals, hospital medical devices.
Guide to PHARMAC, how we work (OPPs), advisory committees, performance, history, people, vacancies.
Whānau health, rongoā medicine, One Heart Many Lives, Te Whaioranga Māori Responsiveness Strategy, PHARMAC whānau.
Named Patient Pharmaceutical Assessment (NPPA) and other channels for exceptional circumstances.
...people using medicines & medical devices, prescribers, pharmacists, suppliers, DHBs.
PHARMAC will be changing the way it makes decisions.
High-quality education seminars for health professionals.
PHARMAC's role in managing hospital medical devices.
We've reached our first funding agreement for a medicine from this process.
Track medicines going through PHARMAC's funding process.
A new framework for funding in exceptional circumstances (including NPPA).
Back to top